Addition of venetoclax to R-CHOP has the potential to improve outcomes for patients with the worst prognosis for diffuse large B-cell lymphoma (DLBCL), those with overexpressed Bcl-2. In the phase 2 CAVALLI study involving 206 patients with advanced stage DLBCL, the addition of venetoclax to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) resulted in ...
Venetoclax ‘vaulting over the wall’ of R-CHOP results in DLBCL
By Michael Woodhead
8 Feb 2021